News List
May 10, 2021
Not intended for U.S. and UK Media

Bayer’s finerenone meets primary endpoint in Phase III FIGARO-DKD cardiovascular outcomes study in patients with chronic kidney disease and type 2 diabetes

April 27, 2021
CEO Werner Baumann at the Annual Stockholders’ Meeting of Bayer AG:

“We’re optimistic for the future”

April 27, 2021

Explanations to the Supervisory Board Report - Prof. Dr. Norbert Winkeljohann

April 27, 2021

Address by Werner Baumann

March 12, 2021

Bayer’s unmatched R&D investment powers industry-leading Crop Science portfolio